PointState Capital’s NovoCure NVCR Stock Holding History

PointState Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-718,900	Closed	-$22.5M	–	170
2018 Q2	$22.5M	Sell	718,900 -130,200	-15%	-$3.62M	0.25%	73
2018 Q1	$18.5M	Buy	+849,100	New	+$18.3M	0.2%	77
2017 Q4	–	Sell	-752,900	Closed	-$14.9M	–	177
2017 Q3	$14.9M	Buy	752,900 +420,900	+127%	+$8.27M	0.13%	96
2017 Q2	$5.74M	Buy	+332,000	New	+$4.29M	0.06%	101

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PointState Capital's NVCR Position: Q3 2018 in Review

PointState Capital sold out of NovoCure (NVCR) in Q3 2018, closing a stake of 718,900 shares — an estimated $22.5M sold.

PointState Capital first reported a position in NVCR in Q2 2017 and held it in 4 quarters. The position peaked at $22.5M in Q2 2018. 176 funds tracked by Wall St. Rank hold NVCR as of Q3 2018.

PointState Capital reported no remaining NovoCure position as of Q3 2018 after selling out during the quarter.
PointState Capital sold 718,900 NovoCure shares in Q3 2018, an estimated $22.5M.
PointState Capital first reported a position in NovoCure in Q2 2017 and held it in 4 quarters.
PointState Capital's NovoCure position peaked at $22.5M in Q2 2018.
176 funds tracked by Wall St. Rank held NovoCure as of Q3 2018.

Based on PointState Capital's 13F filing for Q3 2018, filed 14 Nov 2018.